Q2 Earnings Estimate for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Avadel Pharmaceuticals in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per share of ($0.04) for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.11 EPS, FY2026 earnings at $0.65 EPS and FY2029 earnings at $1.90 EPS.

A number of other analysts have also commented on AVDL. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Avadel Pharmaceuticals in a report on Tuesday, March 4th. UBS Group lowered their price objective on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, January 13th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Avadel Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Wednesday, April 9th. Finally, Piper Sandler dropped their target price on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Avadel Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $19.88.

Avadel Pharmaceuticals Stock Up 2.3 %

Shares of AVDL stock opened at $7.91 on Tuesday. The company has a market capitalization of $764.34 million, a price-to-earnings ratio of -10.01 and a beta of 1.52. Avadel Pharmaceuticals has a 12-month low of $6.38 and a 12-month high of $19.09. The firm has a fifty day moving average of $8.01 and a 200-day moving average of $10.04.

Insider Activity

In related news, Director Linda Palczuk acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was acquired at an average cost of $7.93 per share, for a total transaction of $39,650.00. Following the transaction, the director now directly owns 67,900 shares in the company, valued at $538,447. This trade represents a 7.95 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Avadel Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its holdings in Avadel Pharmaceuticals by 5.7% during the 4th quarter. Janus Henderson Group PLC now owns 14,080,219 shares of the company’s stock worth $148,117,000 after buying an additional 753,332 shares during the period. Two Seas Capital LP grew its stake in Avadel Pharmaceuticals by 90.6% during the fourth quarter. Two Seas Capital LP now owns 4,296,449 shares of the company’s stock worth $45,156,000 after purchasing an additional 2,042,669 shares during the period. Braidwell LP increased its holdings in Avadel Pharmaceuticals by 21.2% in the fourth quarter. Braidwell LP now owns 4,105,726 shares of the company’s stock worth $43,151,000 after purchasing an additional 716,787 shares in the last quarter. Vanguard Group Inc. lifted its stake in Avadel Pharmaceuticals by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 3,953,247 shares of the company’s stock valued at $41,549,000 after buying an additional 90,147 shares during the period. Finally, Wealth Effects LLC boosted its holdings in shares of Avadel Pharmaceuticals by 4.9% during the 4th quarter. Wealth Effects LLC now owns 2,344,130 shares of the company’s stock worth $24,637,000 after buying an additional 110,359 shares in the last quarter. Institutional investors own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.